Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Biochemical Reagents >  Agonist Inhibitors >  5-Pyrimidinecarboxamide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI)

5-Pyrimidinecarboxamide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI)

Basic information Safety Supplier Related

5-Pyrimidinecarboxamide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI) Basic information

Product Name:
5-Pyrimidinecarboxamide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI)
Synonyms:
  • 5-Pyrimidinecarboxamide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI)
  • 5-PyriMidinecarboxaMide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]-
  • JNJ 16241199
  • N-Hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]-5-pyrimidinecarboxamide
  • R 306465
  • N-hydroxy-2-[4-(naphthalen-2-ylsulfonyl)piperazin-1-yl]pyriMidine-5-carboxaMide
  • R306465(JNJ-16241199)
  • JNJ-16241199; JNJ16241199; JNJ 16241199
CAS:
604769-01-9
MF:
C19H19N5O4S
MW:
413.45
Mol File:
604769-01-9.mol
More
Less

5-Pyrimidinecarboxamide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI) Chemical Properties

Density 
1.466
storage temp. 
Store at 0-8 °C
form 
Solid
pka
8.10±0.10(Predicted)
color 
White to off-white
More
Less

5-Pyrimidinecarboxamide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI) Usage And Synthesis

Uses

JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study[1].

in vivo

JNJ-16241199 (R306465) inhibits proliferation in acute lymphoblastic leukaemia (ALL), AML, chronic lymphoblastic leukaemia (CLL), chronic myeloid leukaemia (CML), lymphoma and myeloma tumour cells (IC50 values = 15–486 nM) [1].
JNJ-16241199 inhibits the primary human mammary epithelial cell (HMEC) proliferation with the IC50 of 32 nM, and is insensitive to quiescent, non-proliferative HMEC cells (IC50 = 7815 nM) [1].
JNJ-16241199 (0.1, 0.3, 1 μM, 24-48 h) induces apoptosis and inhibits angiogenesis in A2780 cell line[1].

Animal Model:Human A2780, H460 and HCT116 orthotopic xenograft tumor models[1]
Dosage:10-40 mpk/day for 28 days
Administration:Oral gavage (p.o.)
Result:Induced H3 acetylation and p21waf1, cip1 promoter activity in A2780 ovarian tumour tissue.
Decreased tumour volume in three orthotopic xenograft tumor models.
Reached maximal decrease in final tumour volume to 76–87% in human A2780 orthotopic xenograft tumor models.

IC 50

HDAC1: 3.3 nM (IC50); HDAC8: 23 nM (IC50)

References

[1] Arts J, et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer. 2007;97(10):1344-1353. DOI:10.1038/sj.bjc.6604025

5-Pyrimidinecarboxamide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI)Supplier

QINGDAO CARELONGPHARMATECH CO.,LTD
Tel
053288191853 13061484198
Email
sales@carelongchem.com
Shanghai T&W Pharmaceutical Co., Ltd.
Tel
+86 21 61551611
Hubei XinyuanShun Chemical Co., Ltd.
Tel
13971561712, 13995564702, 027-50664929
Email
hbeixys2001@163.com
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Email
info@adooq.cn
Pharmacodia (Beijing) Co.,Ltd
Tel
+86-400-851-9921
Email
sales@pharmacodia.com